Scarica l'app Stockscreener
72.01
4.96%
3.40
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$68.61
Aprire:
$68.5
Volume 24 ore:
309.19K
Relative Volume:
0.45
Capitalizzazione di mercato:
$2.15B
Reddito:
$442.68M
Utile/perdita netta:
$-77.81M
Rapporto P/E:
-26.99
EPS:
-2.6684
Flusso di cassa netto:
$-28.65M
1 W Prestazione:
+6.32%
1M Prestazione:
-23.91%
6M Prestazione:
+6.74%
1 anno Prestazione:
-38.41%
Intervallo 1D:
$66.35
$72.65
Intervallo di 1 settimana:
$62.01
$69.73
Portata 52W:
$32.21
$170.87
Genedx Holdings Corp Stock (WGS) Company Profile
Nome
Genedx Holdings Corp
Settore
Industria
Telefono
888-729-1206
Indirizzo
333 LUDLOW STREET, STAMFORD
Compare WGS vs TMO, DHR, NTRA, A, IQV
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
WGS
Genedx Holdings Corp
|
72.01 | 2.15B | 442.68M | -77.81M | -28.65M | -2.6684 |
TMO
Thermo Fisher Scientific Inc
|
696.36 | 257.48B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
232.45 | 163.41B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
404.95 | 58.37B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
175.94 | 49.60B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
269.76 | 44.40B | 16.63B | 1.39B | 2.12B | 8.0674 |
Genedx Holdings Corp Stock (WGS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-09 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-10-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-07-09 | Iniziato | Piper Sandler | Overweight |
| 2025-05-15 | Iniziato | Guggenheim | Buy |
| 2025-05-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-08-28 | Iniziato | Wells Fargo | Equal Weight |
| 2024-07-10 | Iniziato | Craig Hallum | Buy |
| 2024-06-03 | Ripresa | Jefferies | Hold |
Mostra tutto
Genedx Holdings Corp Borsa (WGS) Ultime notizie
Encompass Health Expands Rehab Footprint With New Maine Hospital - Zacks Investment Research
GeneDx Holdings (NasdaqGS:WGS) Stock Forecast & Analyst Predictions - Simply Wall Street
GeneDx CEO Katherine Stueland sells $1.03m in stock - Investing.com
GeneDx Director Thomas Fuchs Reports RSU Conversion to 1,146 Shares - Kalkine Media
GeneDx (WGS) CEO sells 10,501 shares to cover taxes - Stock Titan
Tax-driven stock sale by GeneDx (WGS) CFO after RSU vesting - Stock Titan
GeneDx Holdings (WGS) director receives 1,146 shares at no cash cost - Stock Titan
GeneDx (WGS) CEO sells shares in tax-withholding trade - Stock Titan
GeneDx (WGS) CFO sells stock for taxes, holds 41,476 shares - Stock Titan
WGS: GeneDx Holdings Corp Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C - Yahoo Finance
GeneDx at Wells Fargo healthcare conference: growth and collections in focus - Investing.com Canada
GeneDx at Wells Fargo healthcare conference: growth and collections in focus - Investing.com UK
GeneDx Holdings CFO Kevin Feeley Executes 717 Shares at $0 and Sells at $83.84 on Sept. 1, 2026 - Kalkine Media
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against GeneDx Holdings Corp. (WGS) And Encourages Shareholders to Reach Out - ACCESS Newswire
GeneDx Holdings (WGS) CFO sells shares in tax-cover trade - Stock Titan
Insider at GeneDx (NASDAQ: WGS) lines up new stock sale after June tax trades - Stock Titan
Planned $1.2M insider sale at GeneDx (NASDAQ: WGS) tied to 2026 RSU vesting - Stock Titan
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with the Schall Law Firm - Eastern Progress
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree - marketscreener.com
WGS Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Lawsuit Against GeneDx Holdings Corp - Eastern Progress
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics AcquisitionHBSS - Eastern Progress
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit - Eastern Progress
WGS Shareholder Alert: GeneDx Holdings Corp. Securities Class Action LawsuitInvestors Should Contact The Gross Law Firm - Eastern Progress
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Investors to Connect - ACCESS Newswire
GeneDx Holdings (WGS) Study Data Puts Its Fair Value Debate Back In Focus - Sahm
A GeneDx study found genetic diagnoses in 63% of children with faltering growth - Stock Titan
A Look at GeneDx Holdings Corp (WGS) After 5.5% Gain -- GF Value $73.66 vs Price $87.06 - GuruFocus
GeneDx Holdings Corp. $WGS Shares Purchased by Bank of America Corp DE - MarketBeat
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates? - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages GeneDx Holdings Cor - The National Law Review
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-08-18 | GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:WGS | Press Release - Stockhouse
GeneDx: Why I Think The Worst Is Behind The Business (NASDAQ:WGS) - Seeking Alpha
WGS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Inv - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Investors to Connect - ACCESS Newswire
WGS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce - The National Law Review
GeneDx Holdings (WGS) Slips 1.35% to $78.08, Holds Midpoint of Trading RangeCall Flow Alert - Vinanet
GeneDx Holdings (WGS) Slips 1.35% as Shares Hold Between Key Support and ResistanceDelta Hedging - Vinanet
GeneDx Holdings (WGS), Why Is This Fresh Development Drawing Attention? - Sahm
Precision Trading with Genedx Holdings Corp. (WGS) Risk Zones - Stock Traders Daily
The Manufacturers Life Insurance Company Sells 12,820 Shares of GeneDx Holdings Corp. $WGS - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Stockholders to Connect - ACCESS Newswire
Sei Investments Co. Trims Stock Position in GeneDx Holdings Corp. $WGS - MarketBeat
WGS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce - The National Law Review
Is GeneDx Holdings Corp (WGS) Overvalued After 5.1% Rally? GF Va - GuruFocus
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Goldman Sachs Group (WGS) discloses 5.8% beneficial stake in GeneDx Class A - Stock Titan
GeneDx at Canaccord Genuity conference: volume rises, collections lag - Investing.com
Genedx Holdings Corp Azioni (WGS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Genedx Holdings Corp Azioni (WGS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Fuchs Thomas | Director |
Sep 17 '26 |
Option Exercise |
0.00 |
1,146 |
0 |
1,146 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Sep 16 '26 |
Sale |
97.61 |
3,728 |
363,892 |
44,945 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Sep 16 '26 |
Option Exercise |
0.00 |
7,197 |
0 |
48,673 |
| Stueland Katherine | CHIEF EXECUTIVE OFFICER |
Sep 16 '26 |
Sale |
97.61 |
10,501 |
1,025,013 |
115,476 |
| Katherine Stueland | Officer |
Sep 09 '26 |
Proposed Sale |
84.82 |
14,243 |
1,208,100 |
0 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Sep 09 '26 |
Sale |
84.22 |
1,285 |
108,220 |
41,476 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Sep 09 '26 |
Option Exercise |
0.00 |
2,462 |
0 |
42,761 |
| Stueland Katherine | CHIEF EXECUTIVE OFFICER |
Sep 09 '26 |
Sale |
84.22 |
3,692 |
310,932 |
107,227 |
| Stueland Katherine | CHIEF EXECUTIVE OFFICER |
Sep 09 '26 |
Option Exercise |
0.00 |
6,547 |
0 |
110,919 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Sep 01 '26 |
Option Exercise |
0.00 |
717 |
0 |
40,671 |
1.72%
3.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):